- active not recruitingPHASE2
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
This study is testing new medicines, Tobevibart and Elebsiran, against an existing treatment, Bulevirtide. It's for people in the UK who have long-lasting hepatitis delta virus (HDV) infection to see which treatment works best to control the virus and improve liver health.
Belgium · Bulgaria · France - active not recruitingPHASE3
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This study is testing new medicines, tobevibart and elebsiran, for people with chronic hepatitis D. It's a large study looking at how well they work and if they are safe, compared to starting treatment later.
United States · Canada · Georgia - recruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
Austria · France · Germany